We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.025 | 1.56% | 1.625 | 1.60 | 1.65 | 1.675 | 1.60 | 1.60 | 11,401,604 | 10:40:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -0.36 | 1.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/10/2020 07:32 | Can you expand? Based on these late trades? Surely that is announcable | billthebank | |
14/10/2020 07:14 | i think GDR are getting taken over ! | amaretto1 | |
13/10/2020 20:06 | i know now, read it again .. Soz :-) | amaretto1 | |
13/10/2020 19:52 | I was taking the pis!! | peanut100 | |
13/10/2020 14:21 | Forgot India was the only country in the world but cheers for the info though | peanut100 | |
13/10/2020 13:09 | India have their own tests for a cheaper cost they won't be buying gdr tests So that market won't work. Divoc health are small time and they won't get this to the Indian market. India have a number of tests they are using at the moment.So any deals with India are not happening | jayminpatel1 | |
13/10/2020 10:56 | But you buy it ahead of those hopeful revenues hence why all growth stocks trade on racey multiples. If they sign deals you won't be able to buy anywhere near this price again. If nothing signed fair enough will be doomed but that's what makes a market. | peanut100 | |
13/10/2020 10:21 | No there is much more selling as they know gdr hasn't got nothing in sales revenue | jayminpatel1 | |
13/10/2020 09:27 | 2x 850k sells through at 126p the last of CLN's state now gone? | sportbilly1976 | |
12/10/2020 17:28 | Who's buying them all ? | amaretto1 | |
12/10/2020 16:01 | It does not say £1m and you said No orders so a blatant lie. Also you seem clueless on other aspects of GDR and their value. | hooded claw | |
12/10/2020 14:58 | Mcap way over valued at 74m1m of orders is naff allLook at ncyt 450MILLION ORDER FROM GOVERNMENT1m is chump change | jayminpatel1 | |
12/10/2020 14:48 | Can you read ????? " To date, the Company has received over GBP1.0m of indicative orders for the Genedrive(R) 96 SARS-CoV-2 test, but regulatory approvals are required to fulfil these orders and ship the product." | hooded claw | |
12/10/2020 14:43 | None of that has turned into any ordersThey working with divoc health the small scale operation in India.No salesNothing nada | jayminpatel1 | |
12/10/2020 14:41 | Patel needs to learn to read rather than spreading BS Following CE marking of the Genedrive(R) 96 SARS-CoV-2 kit on 22 May, the Company has been actively working to obtain country specific regulatory approvals. The Company has received significant interest from customers and distribution partners for this assay and genedrive has now signed additional distribution contracts in respect of 11 countries to work non-exclusively alongside its existing distributor network. To date, the Company has received over GBP1.0m of indicative orders for the Genedrive(R) 96 SARS-CoV-2 test, but regulatory approvals are required to fulfil these orders and ship the product. | hooded claw | |
12/10/2020 14:39 | Acadia dumped SNG at 37p the day before it shot up to 240p - so ii's know about as much as you especially when you say no sales. Run along patel .... | hooded claw | |
12/10/2020 14:37 | Bgf dumpingRylands dumping So all this big news and they are dumpingThey won't get far gdrHad 1 run to 300pNo salesNo fda approvalNada | jayminpatel1 | |
12/10/2020 08:23 | What the hell? It's about time some in here grew up a bit IMHO | hooded claw | |
11/10/2020 20:35 | As opposed to you | wooster4 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions